vs
Cooper Companies (The)(COO)与Healthpeak Properties(DOC)财务数据对比。点击上方公司名可切换其他公司
Cooper Companies (The)的季度营收约是Healthpeak Properties的1.5倍($1.1B vs $719.4M),Healthpeak Properties净利率更高(73.2% vs 7.9%,领先65.2%),Cooper Companies (The)同比增速更快(4.6% vs 3.1%),Healthpeak Properties自由现金流更多($357.0M vs $149.9M),过去两年Healthpeak Properties的营收复合增速更高(8.9% vs 6.9%)
CooperCompanies是总部位于美国加利福尼亚州圣拉蒙的全球医疗设备企业,旗下设有两大业务单元:主营隐形眼镜生产的库博光学,以及面向女性健康市场提供医疗设备、生育及基因组相关产品的库博外科。
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金,核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建,总部设在科罗拉多州丹佛市,在尔湾、纳什维尔、旧金山均设有办事处,截至2019年12月31日共持有617处物业的权益。
COO vs DOC — 直观对比
营收规模更大
COO
是对方的1.5倍
$719.4M
营收增速更快
COO
高出1.5%
3.1%
净利率更高
DOC
高出65.2%
7.9%
自由现金流更多
DOC
多$207.1M
$149.9M
两年增速更快
DOC
近两年复合增速
6.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $1.1B | $719.4M |
| 净利润 | $84.6M | $114.0M |
| 毛利率 | 61.1% | — |
| 营业利润率 | 13.2% | 17.4% |
| 净利率 | 7.9% | 73.2% |
| 营收同比 | 4.6% | 3.1% |
| 净利润同比 | -28.0% | 2406.4% |
| 每股收益(稀释后) | $0.42 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
COO
DOC
| Q4 25 | $1.1B | $719.4M | ||
| Q3 25 | $1.1B | $705.9M | ||
| Q2 25 | $1.0B | $694.3M | ||
| Q1 25 | $964.7M | $702.9M | ||
| Q4 24 | $1.0B | $698.0M | ||
| Q3 24 | $1.0B | $700.4M | ||
| Q2 24 | $942.6M | $695.5M | ||
| Q1 24 | $931.6M | $606.6M |
净利润
COO
DOC
| Q4 25 | $84.6M | $114.0M | ||
| Q3 25 | $98.3M | $-117.1M | ||
| Q2 25 | $87.7M | $31.7M | ||
| Q1 25 | $104.3M | $42.8M | ||
| Q4 24 | $117.5M | $4.5M | ||
| Q3 24 | $104.7M | $85.9M | ||
| Q2 24 | $88.9M | $146.0M | ||
| Q1 24 | $81.2M | $6.7M |
毛利率
COO
DOC
| Q4 25 | 61.1% | — | ||
| Q3 25 | 65.3% | 58.6% | ||
| Q2 25 | 67.8% | 60.2% | ||
| Q1 25 | 68.4% | 61.1% | ||
| Q4 24 | 66.5% | 60.3% | ||
| Q3 24 | 66.1% | 60.0% | ||
| Q2 24 | 67.0% | 60.6% | ||
| Q1 24 | 67.0% | 59.8% |
营业利润率
COO
DOC
| Q4 25 | 13.2% | 17.4% | ||
| Q3 25 | 16.6% | 9.2% | ||
| Q2 25 | 18.4% | 5.7% | ||
| Q1 25 | 18.9% | 7.7% | ||
| Q4 24 | 19.5% | -2.2% | ||
| Q3 24 | 19.2% | 14.1% | ||
| Q2 24 | 17.2% | 22.3% | ||
| Q1 24 | 16.4% | 3.7% |
净利率
COO
DOC
| Q4 25 | 7.9% | 73.2% | ||
| Q3 25 | 9.3% | -16.6% | ||
| Q2 25 | 8.7% | 4.6% | ||
| Q1 25 | 10.8% | 6.1% | ||
| Q4 24 | 11.5% | 0.7% | ||
| Q3 24 | 10.4% | 12.3% | ||
| Q2 24 | 9.4% | 21.0% | ||
| Q1 24 | 8.7% | 1.1% |
每股收益(稀释后)
COO
DOC
| Q4 25 | $0.42 | $0.16 | ||
| Q3 25 | $0.49 | $-0.17 | ||
| Q2 25 | $0.44 | $0.05 | ||
| Q1 25 | $0.52 | $0.06 | ||
| Q4 24 | $0.59 | $0.02 | ||
| Q3 24 | $0.52 | $0.12 | ||
| Q2 24 | $0.44 | $0.21 | ||
| Q1 24 | $0.41 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $110.6M | $467.5M |
| 总债务越低越好 | $2.5B | $9.8B |
| 股东权益账面价值 | $8.2B | $7.5B |
| 总资产 | $12.4B | $20.3B |
| 负债/权益比越低杠杆越低 | 0.30× | 1.31× |
8季度趋势,按日历期对齐
现金及短期投资
COO
DOC
| Q4 25 | $110.6M | $467.5M | ||
| Q3 25 | $124.9M | $91.0M | ||
| Q2 25 | $116.2M | $89.4M | ||
| Q1 25 | $100.9M | $70.6M | ||
| Q4 24 | $107.6M | $119.8M | ||
| Q3 24 | $109.7M | $180.4M | ||
| Q2 24 | $112.4M | $106.9M | ||
| Q1 24 | $135.2M | $101.8M |
总债务
COO
DOC
| Q4 25 | $2.5B | $9.8B | ||
| Q3 25 | $2.4B | $9.1B | ||
| Q2 25 | $2.5B | $9.0B | ||
| Q1 25 | $2.5B | $8.9B | ||
| Q4 24 | $2.6B | $8.7B | ||
| Q3 24 | $2.6B | $8.6B | ||
| Q2 24 | $2.7B | $8.6B | ||
| Q1 24 | $2.7B | $8.8B |
股东权益
COO
DOC
| Q4 25 | $8.2B | $7.5B | ||
| Q3 25 | $8.4B | $7.6B | ||
| Q2 25 | $8.3B | $7.9B | ||
| Q1 25 | $8.1B | $8.2B | ||
| Q4 24 | $8.1B | $8.4B | ||
| Q3 24 | $7.9B | $8.6B | ||
| Q2 24 | $7.8B | $8.8B | ||
| Q1 24 | $7.7B | $8.9B |
总资产
COO
DOC
| Q4 25 | $12.4B | $20.3B | ||
| Q3 25 | $12.4B | $19.6B | ||
| Q2 25 | $12.4B | $19.8B | ||
| Q1 25 | $12.2B | $19.8B | ||
| Q4 24 | $12.3B | $19.9B | ||
| Q3 24 | $12.1B | $20.0B | ||
| Q2 24 | $12.0B | $20.2B | ||
| Q1 24 | $12.0B | $20.5B |
负债/权益比
COO
DOC
| Q4 25 | 0.30× | 1.31× | ||
| Q3 25 | 0.29× | 1.20× | ||
| Q2 25 | 0.30× | 1.14× | ||
| Q1 25 | 0.31× | 1.08× | ||
| Q4 24 | 0.32× | 1.04× | ||
| Q3 24 | 0.33× | 1.00× | ||
| Q2 24 | 0.34× | 0.98× | ||
| Q1 24 | 0.35× | 0.99× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $247.9M | $1.3B |
| 自由现金流经营现金流 - 资本支出 | $149.9M | $357.0M |
| 自由现金流率自由现金流/营收 | 14.1% | 49.6% |
| 资本支出强度资本支出/营收 | 9.2% | 124.4% |
| 现金转化率经营现金流/净利润 | 2.93× | 10.99× |
| 过去12个月自由现金流最近4个季度 | $433.7M | — |
8季度趋势,按日历期对齐
经营现金流
COO
DOC
| Q4 25 | $247.9M | $1.3B | ||
| Q3 25 | $261.4M | $315.0M | ||
| Q2 25 | $96.2M | $363.5M | ||
| Q1 25 | $190.6M | $279.4M | ||
| Q4 24 | $268.1M | $1.1B | ||
| Q3 24 | $207.5M | $318.2M | ||
| Q2 24 | $111.0M | $316.2M | ||
| Q1 24 | $122.7M | $152.6M |
自由现金流
COO
DOC
| Q4 25 | $149.9M | $357.0M | ||
| Q3 25 | $164.5M | — | ||
| Q2 25 | $18.1M | — | ||
| Q1 25 | $101.2M | — | ||
| Q4 24 | $128.1M | $333.7M | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $36.9M | — | ||
| Q1 24 | $4.6M | — |
自由现金流率
COO
DOC
| Q4 25 | 14.1% | 49.6% | ||
| Q3 25 | 15.5% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | 12.6% | 47.8% | ||
| Q3 24 | 11.8% | — | ||
| Q2 24 | 3.9% | — | ||
| Q1 24 | 0.5% | — |
资本支出强度
COO
DOC
| Q4 25 | 9.2% | 124.4% | ||
| Q3 25 | 9.1% | — | ||
| Q2 25 | 7.8% | — | ||
| Q1 25 | 9.3% | — | ||
| Q4 24 | 13.7% | 105.6% | ||
| Q3 24 | 8.9% | — | ||
| Q2 24 | 7.9% | — | ||
| Q1 24 | 12.7% | — |
现金转化率
COO
DOC
| Q4 25 | 2.93× | 10.99× | ||
| Q3 25 | 2.66× | — | ||
| Q2 25 | 1.10× | 11.48× | ||
| Q1 25 | 1.83× | 6.52× | ||
| Q4 24 | 2.28× | 235.43× | ||
| Q3 24 | 1.98× | 3.71× | ||
| Q2 24 | 1.25× | 2.17× | ||
| Q1 24 | 1.51× | 22.85× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
COO
| Sphere Other | $365.0M | 34% |
| Toric And Multifocal | $344.7M | 32% |
| Office And Surgical | $214.5M | 20% |
| Fertility | $140.9M | 13% |
DOC
暂无分部数据